Trial Profile
Phase I trial investigating the tolerability, pharmacokinetics and pharmacodynamics of olaratumab in patients with cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Jan 2007
Price :
$35
*
At a glance
- Drugs Olaratumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors ImClone Systems
- 15 Jan 2007 New trial record.